Scarica l'app Stockscreener
2.61
0.00%
0.00
Dopo l'orario di chiusura:
2.66
0.05
+1.92%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
ESPR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Esperion Therapeutics, Inc. (ESPR) latest stock news and headlines - Yahoo Finance Singapore
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio - The Globe and Mail
Esperion sells Japan royalty rights for $50 million to Athyrium By Investing.com - Investing.com Canada
Esperion Therapeutics, Inc. (ESPR) stock price, news, quote and history - Yahoo Finance UK
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines - MSN
Athyrium Capital Management and Esperion Therapeutics Inc. (NASDAQ: ESPR) have signed a Japanese royalty financing agreement worth $50 million - Bitget
Esperion Therapeutics, Athyrium Capital Management Sign $50 Million Japan Royalty Financing - MarketScreener
Esperion Therapeutics Inc. has successfully secured financing, which will be specifically used to support its acquisition of Corstasis Therapeutics. - Bitget
Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund. - Bitget
Esperion Adds $25 Million Term Loans, Sells $50 Million Otsuka Royalties to Fund Corstasis Buy - TradingView
Esperion (ESPR) acquires Corstasis, adds $25M term loan and $50M royalty sale - Stock Titan
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics - The Manila Times
Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) - The Manila Times
Esperion completes acquisition of Corstasis Therapeutics - Investing.com
Athyrium Capital Management and Esperion Enter Into $50 - GlobeNewswire
Esperion Therapeutics ranks 88 among 300 on Americas Fastest Growing Companies list - Traders Union
Zacks Research Has Negative Forecast for ESPR Q2 Earnings - MarketBeat
Esperion Presents New Data from CLEAR Outcomes Highlighting Value of Bempedoic Acid at ACC.26 - dicardiology.com
New Analyst Updates: $9 and $16 Price Targets on Esperion Therapeutics Signal Major Upside From $2.63 - Moomoo
Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst - MarketBeat
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing - citybiz
Esperion Therapeutics Inc (ESPR) strengthens business outlook amid strategic agreements - MSN
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference - Bitget
Esperion to acquire Corstasis for $75M upfront payment - MSN
Esperion Therapeutics (NASDAQ:ESPR) Trading Up 9.7%Here's What Happened - MarketBeat
Investors can watch Esperion at Needham's virtual healthcare event - Stock Titan
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16 - Moomoo
US Market Wrap: Can Esperion Therapeutics Inc outperform under higher oil prices2026 Technical Overview & Free Community Consensus Stock Picks - baoquankhu1.vn
Needham Virtual Healthcare Conference features Esperion Therapeutics at 25th anniversary session - Traders Union
Esperion reports bempedoic acid cut ischemic stroke risk by 22% - Investing.com Canada
Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL (bempedoic acid) at the American College of Cardiology's Annual Scientific Session 2026 - Bitget
Esperion Therapeutics unveils new CLEAR Outcomes data on NEXLETOL at ACC Annual Scientific Session - Traders Union
Esperion Showcases New Data from CLEAR Outcomes - GlobeNewswire
Tech Rally: Is Esperion Therapeutics Inc in a bullish channelM&A Rumor & Growth Focused Entry Reports - baoquankhu1.vn
Vanguard (ESPR) Amendment: Reports zero ESPR common shares after internal realignment - Stock Titan
Esperion Therapeutics (NASDAQ:ESPR) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Esperion shares rise 8% after revenue tops forecasts and acquisition announced - MSN
Dip Buying: Does Esperion Therapeutics Inc align with a passive investing strategy2026 Sector Moves & Free Reliable Trade Execution Plans - baoquankhu1.vn
Esperion acquires Enbumyst maker Corstasis - MSN
Esperion Therapeutics prices $75M public offering - MSN
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines - Insider Monkey
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down - MSN
Insider Selling: Esperion Therapeutics (NASDAQ:ESPR) Insider Sells $15,411.60 in Stock - MarketBeat
Esperion Therapeutics CFO Halladay sells $17k in stock By Investing.com - Investing.com India
Esperion Therapeutics CEO Koenig sells $69,546 in stock By Investing.com - Investing.com Canada
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):